Autifony Therapeutics
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 26.7m | 18.8m | <1m | <1m | 1.2m | 1.2m |
| % growth | (64 %) | 3878 % | (29 %) | (98 %) | 117 % | 42 % | (5 %) |
| EBITDA | (3.4m) | 18.4m | 9.1m | (9.0m) | (6.3m) | (7.7m) | - |
| % EBITDA margin | (506 %) | 69 % | 48 % | (2284 %) | (737 %) | (631 %) | - |
| Profit | (2.0m) | 19.5m | 9.7m | (8.1m) | (5.6m) | (6.7m) | - |
| % profit margin | (297 %) | 73 % | 51 % | (2051 %) | (653 %) | (553 %) | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€7.0m | Early VC | ||
N/A | Spinout | ||
$5.5m | Series A | ||
€3.1m | Early VC | ||
£8.0m | Series A | ||
| N/A | £1.3m | Early VC | |
| Total Funding | €26.2m | ||
Related Content
Recent News about Autifony Therapeutics
EditAutifony Therapeutics is a UK-based pharmaceutical company focused on developing innovative drugs to treat hearing disorders and serious diseases of the central nervous system. The company operates in the biopharmaceutical market, targeting conditions such as schizophrenia, Fragile X syndrome, and various hearing disorders. Autifony's business model revolves around the research and development of novel therapeutics, particularly those involving Kv3 ion channels, which play a crucial role in neuronal signaling. The company generates revenue through the development and potential commercialization of these drugs, as well as through partnerships and licensing agreements. Autifony serves a range of clients including healthcare providers, research institutions, and pharmaceutical companies.
Keywords: biopharmaceutical, hearing disorders, central nervous system, schizophrenia, Fragile X, Kv3 ion channels, novel therapeutics, drug development, UK-based, pioneering science.